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Introduction
The formation of reactive oxygen species (ROS) is essential for normal cell physiology, and has been covered in detail in many excellent recent reviews [1] [2] [3] [4] . Only a few aspects, which lay the groundwork for discussing specific ROS functions in leukemic cells, shall be briefly reiterated here.
One important type of ROS are superoxide anions (O 2 .- ) as they are produced as side-products along the respiratory chain in mitochondria [5] , by activity of NADPH oxidases 1-3, and 5 [4] , or by different other cellular oxidases. Hydrogen peroxide (H 2 O 2 ), considered a particular important signaling molecule [6] , can be produced by NADPH oxidase 4 (NOX4) and the Dual oxidases 1 and 2 (DUOX1, 2), or by conversion of superoxide anions through superoxide dismutases (SOD). Further reactive species such as the short-lived hydroxyl radical (OH . ), lipid hydroperoxides, peroxynitrite (NO 3 -) or hypochloric acid (HOCl) arise by metabolic reactions engaging superoxide or H 2 O 2 ( Fig.1 ).
Among the specific physiologic functions of ROS is the reversible modification of proteins in the course of signal transduction in many cell types. Some of these modifications may not occur by direct interaction with any of the listed ROS species, but instead be relayed through intermediate oxidation products [3] . The formation of ROS and their reaction products is limited in time and extent by efficient cellular "anti-oxidant" systems. For example, peroxiredoxins (PRDXs) and catalase rapidly decompose H 2 O 2 . Thioredoxins and glutathione peroxidases can revert oxidative modifications, e.g.
of oxidized protein-thiols or of lipid hydroperoxides, respectively. These and further antioxidant systems require NADPH and GSH for their restoration. The expression of several antioxidant proteins/enzymes is under positive control of the transcription factor NRF2, whose protein level and thereby activity is promoted by modification of an upstream "oxidant sensor" designated KEAP1
( Fig. 1 ). If ROS formation exceeds the capacity of the antioxidant mechanisms, cells are exposed to "oxidative stress", leading to damage of cellular macromolecules, and potentially cell death.
Different types of cancer cells appear to produce higher levels of ROS than their normal counterparts [7, 8] . For example, early reports described enhanced ROS production in RAS-transformed fibroblasts [9] , a finding which has later been corroborated in human CD34-positive hematopoietic progenitor cells [10] . More recently, also enhanced antioxidant activities were noted in cancer cells, for example as consequence of RAS-mediated transformation [11] . Consistent with a contributing role of this mechanism to tumor formation or maintenance, mutations in components of the KEAP1-NRF2 axis were found in different tumor types, leading to constitutive NRF2 activation [12] [13] [14] . It is likely that enhanced antioxidant capacity in some tumor entities is required for enabling cell survival under conditions of enhanced ROS production. ROS formation plays also a role in the interaction of cancer cells with their microenvironment, such as the cancer stem cell niche, with inflammatory cells or in the context of tumor angiogenesis. Clearly, alterations in ROS metabolism in cancer are complex,
presumably specific for certain cancer entities, and relate to both alterations in ROS formation and antioxidant defense. Increased ROS levels upon cytokine stimulation; low PRDX2 levels correlated with poor prognosis [29] A plethora of data has indicated alterations in ROS metabolism in leukemia, either linked to etiology, prognosis or therapy responses [30, 31] . Many studies have supported the idea that ROS formation M A N U S C R I P T
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may indeed causally contribute to leukemia growth and malignancy. For example, primary AML patient cells have been shown to frequently produce high levels of superoxide, a phenomenon which could be causally related to AML cell proliferation [25] . Only relatively recently, however, insights into the molecular basis of ROS formation in the leukemic cells were obtained. Importantly, the activity of key oncoproteins in myeloid leukemia, comprising BCR-ABL, FMS-like tyrosine kinase 3 with internal tandem duplications (FLT3-ITD), and Janus kinase 2 (JAKL2) V617F could be mechanistically connected to metabolic alterations leading to enhanced ROS formation (Table 1, Chapter 2). We will summarize here recent findings on these mechanisms, focusing on FLT3-ITDdriven ROS production in AML and its consequences.
Oncogenic kinases as drivers of ROS formation in myeloid leukemia
More than 90% of chronic myelogenous leukemia (CML) cases develop from a chromosomal abnormality known as the Philadelphia chromosome, which result from a reciprocal translocation between chromosomes 9 and 22, generating the chimeric kinase BCR-ABL (reviewed in [32] ). BCR-ABL is known to activate down-stream pro-survival pathways, for example, PI3K/AKT, JAK/STAT and RAF/MEK/ERK, resulting in resistance to apoptosis and proliferation [33] . BCR-ABL expressing cells have been shown to generate increased levels of ROS compared to untransformed cells [16] .
Various sources of ROS have been examined in CML including leakage from the mitochondrial electron transport chain and NADPH oxidase generated ROS, particularly NOX4. Naughton et al., demonstrated NOX4-generated ROS contributing significantly to total endogenous ROS upon BCR-ABL induction [34] . and RAF/MEK/ERK activation and GSK3β inhibition [36] . Mitochondrial ROS also appear to contribute to total ROS in CML cells.
The JAK2 V617F mutation is a substitution of a valine for a phenylalanine at amino acid 617 of JAK2 destabilizing the JH2 "pseudokinase" domain of JAK2. It results in loss of the auto-inhibitory function of this regulatory domain, and in turn constitutive tyrosine kinase activity [37] . The mutation is present in approximately 6% of myelodysplastic syndromes (MDS) and 50% of myeloproliferative neoplasms (MPNs) [38] . Signaling of the JAK2 V617F oncoprotein results in constitutive activation of downstream pro-survival signaling, including activation of STAT5, PI3K/AKT and RAF/MEK/ERK, and in turn the formation of ROS [39, 40] . The increase in ROS is concurrent with M A N U S C R I P T
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elevated levels of DNA damage [40] . In neutrophils from JAK2 V617F positive patients, an increased phosphorylation of the NOX2 subunit p47 phox on Ser345 has been observed, suggesting a contribution of NOX2 activation to elevated levels of ROS in MDS [41] .
FLT3, encoding the class III receptor tyrosine kinase FLT3 is the most frequently mutated gene in AML (up to 35%) [42, 43] . The prevalent mutations (found in 20-25% of AML patients) encode internal tandem duplications of sequence in the FLT3 juxtamembrane or the first part of the kinase domain, giving rise to FLT3-ITD oncoproteins. Since the affected kinase regions have a negative regulatory function for kinase activity, FLT3-ITD mutations result in ligand independent constitutive activation of the FLT3 receptor both at the plasma membrane but also of the newly synthesized kinase at the endoplasmic reticulum [44, 45] . Occurrence of FLT3-ITD has been associated with a worse patient prognosis [46] [47] [48] . Constitutive activity of FLT3-ITD activates down-stream pro-survival signaling pathways including PI3K/AKT, STAT5 (whereby STAT5 activation is independent of JAK kinase activation [49] ) and RAF/MEK/ERK, which are known to promote survival, proliferation and transformation [50] [51] [52] . Recent findings have identified that in order for PI3K/AKT and RAF/MEK/ERK pro-survival pathways to be activated they must be located down-stream of FLT3-ITD at the plasma membrane and STAT5 is located down-stream of FLT3-ITD at the ER [45, 53] .
FLT3-ITD expressing cell lines have been shown to produce increased levels of ROS, DNA oxidation and double strand breaks (dsbs) when compared to FLT3-WT expressing cell lines [22, 27] . NOXgenerated ROS appear to be a primary source of ROS in FLT3-ITD expressing AML cells. Cells harboring the FLT3-ITD mutant have been shown to produce increased levels of NOX2 and NOX4
and their partner protein p22 phox compared to wild type FLT3 cells [26, 28] . Also, stimulation of The enhanced ROS formation in FLT3-ITD expressing AML cells serves a signaling function in that it promotes cell proliferation and migration, and thereby contributes to leukemic cell transformation [21, 27] . In addition, FLT3-ITD driven ROS formation has been associated with DNA damage and accumulation of mutations [22, 23, 26] . Both aspects will be discussed in the following parts.
ROS mediated alteration of transforming signal transduction: role of PTP oxidation.
Protein phosphorylation of tyrosine residues plays a fundamental role in diverse cellular functions such as proliferation, growth, metabolism and differentiation. Protein-tyrosine kinases (PTKs) mediated signal transduction is regulated by protein-tyrosine phosphatases (PTPs) and failure of regulation of either protein family can contribute to unfavorable diseases like cancer. The human PTP M A N U S C R I P T
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7 superfamily consists of more than 100 members. Many of these enzymes are identified by the unique consensus signature motif HCX 5 R involved in the catalytic function. Despite of their sequence and structural similarity, PTPs show a wide range of substrate specificity [54, 55] .
In AML, several members of the PTP superfamily were found to be altered by genetic aberration, promoter methylation or gene overexpression. PTPN11 (also known as SHP-2) positively regulates FL ligand mediated FLT3 receptor signaling [56] and not surprisingly, activating mutations (commonly found SHP-2 E76K mutant) were identified in AML [57, 58] . Phosphatase PTEN negatively regulates PI3K signaling downstream of FLT3 receptor and is also mutated, though rarely in AML [59] . Several recent findings claim a role for deregulated gene expression of dual specificity phosphatases such as PRL2, PRL3 and DUSP6 in AML cases with and without FLT3 mutation [60] [61] [62] . Recently STS1 and STS2 (also known as UBASH3B and UBASH3A), which belong to a PTP subfamily with histidine-based catalysis [54] , were identified to be directly regulating the FLT3 receptor tyrosine phosphorylation in hematopoietic stem cells [63] . However, their potential role in regulating constitutively active FLT3-ITD phosphorylation or FLT3 signaling in AML is yet unknown. Other examples include the transmembrane PTP PTPRD (PTPδ), which is downregulated by promoter methylation and may be a tumor suppressor in pediatric AML [64] , and CDC25, which is mutated in familial platelet disorder with predisposition to AML [65] .
PTPs can modulate signal transduction in many ways, both negatively and positively. For example, they prevent the non-specific activation of PTKs, e.g. by averting the ligand-independent activation of RTKs. In other contexts, PTPs can promote signaling by activation of SRC family kinases or of the RAS pathway [55] . PTP activity is regulated by several mechanisms [66] and one such regulatory process is the reversible oxidation of the catalytic cysteine by ROS. H 2 O 2 is considered an important ROS species in the PTP oxidation process. Upon oxidation, the active-site thiol moiety (-SH) is converted to a sulfenyl moiety (-SOH), which further reacts to more stable reaction products in intramolecular reactions, like sulfenylamides or disulfides. The widely presumed role of H 2 O 2 in PTP oxidation may in fact be indirect [3] and other oxidants, such as lipid peroxides, can also effectively oxidize PTPs [67, 68] . PTP oxidation is typically transient, and reduction back to the active state is accomplished by interaction with cellular antioxidants like GSH or thioredoxin [67] . Reversible PTP inactivation facilitates the efficient RTK signal transduction in the cells upon ligand/growth factor stimulation [1] . Emerging reports claim, however, that PTPs are also important targets of pathologically generated ROS and that in such circumstances ROS mediated PTP inactivation could contribute to diseases like cancer. In support that such processes play a role in leukemia, an early study showed that high ROS levels in BCR-ABL transformed cells were associated with low levels of overall PTP activity, and treatment with antioxidants reverted these effects [15] . As outlined above, apart from BCR-ABL, also other myeloid leukemia-specific PTK oncoproteins, JAK2 V617F and
FLT3-ITD, cause constitutive formation of elevated levels of ROS and their possible consequences
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for PTP deregulation deserve attention. The transmembrane PTP PTPRJ (also known as DEP-1, and CD148) was previously identified as bona fide PTP negatively regulating FLT3 receptor signaling in myeloid cells [69] . DEP-1 regulates FL ligand-induced FLT3 receptor signaling by associating with [70] and dephosphorylating FLT3 directly, thereby attenuating the activation of FLT3. When the role of DEP-1 for regulation of the FLT3-ITD oncoprotein was analyzed, DEP-1 was discovered to be oxidized and partially inactivated due to high levels of sustained ROS generation leading to elevated FLT3 activity and promotion of downstream signaling pathways, including STAT5 and RAS/ ERK1/2 activation, causally contributing to cellular transformation [27] . Investigating the relevant ROS sources it could recently be convincingly shown that NOX4 mRNA and protein expression are 
ROS-mediated DNA damage and potential implications for leukemia biology
Genomic instability has been suggested to be the main cause of genetic diversity in cancer [71, 72] . Also disease progression in leukemia is associated with the accumulation of multiple mutated genes, resulting in resistance to apoptosis, abnormal cell growth and a block in differentiation [43, 73] . To explain the multiple mutations, the leukemic cells must likely acquire some form of genetic instability. Increasing evidence has shown that an increase in ROS formation, which is M A N U S C R I P T
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9 associated with an increased DNA damage, may be important in this context. Oxidative DNA damage can cause a wide range of DNA alterations such as base pair mutations, insertions and deletions [74] .
DSBs are one of the most dangerous lesions resulting in translocations and deletions. Alternative mechanisms involved in the generation of genomic instability include unfaithful or insufficient repair of DNA damage [75] . There are two DNA repair systems responsible for DNA dsb repair: a precise homologous recombination and a less precise non-homologous end-joining (NHEJ). Increased activity of the unfaithful AEJ repair pathway and down-regulation of the faithful NHEJ pathway were found associated with FLT3-ITD and BCR-ABL oncogenic signaling [23, 76, 77] . For example, an earlier study revealed that inhibition of FLT3-ITD using PKC412 resulted in significant decrease in dsbs and non-homologous repair of DNA damage. On the other hand, PKC412 had no effect on dsbs or the DNA repair pathways in FLT3-WT expressing cells [78] , showing the importance and involvement of FLT3-ITD oncogene in genomic instability. It was also shown that increased repair of FLT3-ITD stimulated DNA damage contributes to drug resistance, which coincides with the high relapse rate associated with FLT3-ITD expressing AML cases [78] . The BCR/ABL mutation in CML is involved in a cycle of genomic instability similar to the FLT3-ITD mutation. The oncogenic effects of BCR/ABL cause increased levels of ROS production leading to enhanced DNA damage and compromised DNA repair [79] . Not only levels of DNA damage are much higher in BCR/ABL transformed cells compared to non-transformed cells, also the rate of DNA repair by unfaithful end joining systems is much higher. Importantly, the resulting accumulation of DNA damage and genetic abnormalities contributes to resistance against drugs that are commonly used in the treatment of CML including Imatinib [80, 81] .
As outlined above, FLT3-ITD expressing cells have been shown to generate increased levels of ROS. p22 phox and p22 phox dependent NOX isoforms, particularly NOX4, have been shown to be the primary source of ROS in FLT3-ITD expressing cells [24, 28] . Recently, further research has therefore been carried out to investigate the specific pathways leading to ROS formation and ROSmediated DNA damage and genomic instability in FLT3-ITD positive AML cells [26] . Emerald 1 (NucPE1). NOX4 and p22 phox were shown to co-localize in the nucleus, thus reinforcing that nuclear NOX activity may contribute to genomic instability in AML [26] . FLT3-ITD expressing 32D cells exhibited a 100% increase in endogenous H 2 O 2 compared to FLT-WT expressing cells as quantified by flow cytometry using the H 2 O 2 specific probe Peroxy Orange 1 (PO1), and a 25% increase in nuclear H 2 O 2 . There was, however, no significant difference in mitochondrial generated ROS between FLT3-ITD-and FLT3-WT-expressing cells. FLT3-ITD mediated DNA damage was M A N U S C R I P T
characterized using two different readouts: Phosphorylated histone H2AX (γH2AX), one of the most widely used marker for detecting DNA dsbs [82] , and 8-hydroxy-2' deoxyguanosine (8-OHdG), the predominant form of ROS-induced DNA lesion, also widely used as a marker of oxidative stress [83] . (Figure 3 ).
Unfortunately, ROS-mediated damage in AML and CML has major implications in the treatment of leukemia. It is increasingly more difficult to treat leukemia due to the accumulation in genetic abnormalities leading to resistance to protein tyrosine kinases inhibitors, for example, PKC412 and imatinib and further progression of the malignancy (Fig. 3) .
Future directions
Despite the significant advances in understanding mechanisms of ROS formation in myeloid [84] may be helpful in identifying these targets. More work will also be needed to further establish the putative causal role of ROS formation for the biology of myeloid leukemia. For example, mouse strains with constitutive or conditional deficiency of NOX enzymes and several regulators are available [85] and may be investigated in transplantation-based or transgenic leukemia models. These studies may help in establishing components in the pathways for ROS formation in cells of myeloid leukemia as candidate drug targets. Inhibition of AML-cell proliferation and attenuation of the development of a FLT3-ITD driven myeloproliferative disease in mice by compounds reported to inhibit NOX4 have been recent promising findings [28] . However, many currently available compounds for interference with ROS formation are not entirely specific or controversial with respect to their mechanism of action [86] . Given the importance of NOX mediated ROS formation not only in leukemia but many other pathological contexts, the improvement of compounds can be expected and their testing in leukemia models will be an exciting perspective. 
